Surrozen (SRZN) Expected to Announce Quarterly Earnings on Friday

Surrozen (NASDAQ:SRZN) is projected to release its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($1.0920) per share and revenue of $4.00 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The firm had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 4,055.04%. On average, analysts expect Surrozen to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Surrozen Price Performance

Surrozen stock opened at $32.64 on Wednesday. The company has a market cap of $375.03 million, a price-to-earnings ratio of -0.98 and a beta of 0.59. Surrozen has a 12 month low of $5.90 and a 12 month high of $35.00. The stock’s 50-day moving average is $28.27 and its 200-day moving average is $22.11.

Insider Buying and Selling

In other Surrozen news, VP Yang Li sold 1,584 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $52,794.72. Following the completion of the sale, the vice president owned 17,216 shares of the company’s stock, valued at $573,809.28. This trade represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the company’s stock in a transaction dated Tuesday, March 24th. The shares were purchased at an average price of $24.69 per share, for a total transaction of $2,633,386.02. Following the purchase, the insider directly owned 736,554 shares of the company’s stock, valued at approximately $18,185,518.26. This trade represents a 16.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 189,734 shares of company stock worth $4,677,729 and have sold 8,144 shares worth $271,440. 31.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On Surrozen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRZN. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen during the fourth quarter valued at about $99,000. Marshall Wace LLP purchased a new position in Surrozen in the fourth quarter valued at about $247,000. Ieq Capital LLC purchased a new position in Surrozen in the fourth quarter valued at about $304,000. OMERS ADMINISTRATION Corp acquired a new stake in Surrozen during the 4th quarter valued at approximately $310,000. Finally, Citadel Advisors LLC increased its holdings in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. 66.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on SRZN shares. TD Cowen assumed coverage on shares of Surrozen in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective (up from $32.00) on shares of Surrozen in a research report on Tuesday, March 24th. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Surrozen in a report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Surrozen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Surrozen has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.